Sprycel (Dasatinib) 
Copay Assistance Program

QuickRx Specialty Pharmacy helps patients access copay assistance for dasatinib by identifying and applying for every patient assistance program and foundation grant they qualify for. Eligible patients may pay as little as $0 per month.

If you already have a manufacturer copay card, QuickRx can apply it to your prescription at the time of dispensing, if applicable. Our team handles the coordination and ships generic dasatinib nationwide. Call (917) 830-2525 for a free, no-obligation cost estimate.

Yes. QuickRx never charges patients for copay assistance enrollment support. Our patient navigators research every program you may qualify for, complete the applications, and monitor your enrollment through renewals, all at no cost to you. The only thing you may pay is what your insurance or assistance program requires after enrollment.

Eligibility depends on the program. Foundation grants and patient assistance programs may help government-insured or underinsured patients based on income, diagnosis, and U.S. residency. If you have a manufacturer copay card, QuickRx can apply it to your prescription at dispensing, if applicable.

Eligible patients MAY pay $0 depending on their plan and program. The fastest way to know what you qualify for is to call (917) 830-2525.

Yes. If you have already received a manufacturer copay card from your prescriber or through the drug manufacturer, QuickRx can apply it to your generic dasatinib prescription at the time of dispensing, if applicable. QuickRx does not issue, provide, or enroll patients in manufacturer copay card programs. Call (917) 830-2525 or fill out the form on this page and let your navigator know you have a card.

Manufacturer copay cards typically exclude patients with Medicare or Medicaid. However, Medicare patients are not without options. Foundation grants and patient assistance programs are frequently available to Medicare patients who meet income and diagnosis requirements. The 2025 Inflation Reduction Act also capped Medicare Part D out-of-pocket costs at $2,000 per year, which has reduced the burden for many oncology patients. QuickRx specializes in matching patients to the right program for their coverage type.

Savings vary widely depending on your insurance and the specific program you qualify for. Eligible patients MAY pay as little as $0 per month. The fastest way to get an accurate estimate for your situation is to call (917) 830-2525.

The cost of dasatinib depends on whether you take brand-name Sprycel or generic dasatinib, and on your insurance. Brand-name Sprycel carries a high list price; generic dasatinib is available from multiple manufacturers and is often substantially less expensive. The chart below shows representative reference prices only — not what you will pay.

Your actual out-of-pocket cost depends on your plan, deductible, and any assistance programs you qualify for. QuickRx can tell you what you would actually owe after insurance and assistance. Call (917) 830-2525.

Yes. Generic dasatinib tablets are available from multiple manufacturers and are often substantially less expensive than brand-name Sprycel. Generic dasatinib comes in the same strengths as the brand: 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg tablets. QuickRx dispenses generic dasatinib and can check whether it is covered under your plan. Learn more in our brand vs generic dasatinib comparison.

Yes. Generic dasatinib contains the same active ingredient, at the same strength and dosage form, as brand Sprycel. The FDA requires generic drugs to meet the same standards for safety, efficacy, and quality as their brand-name counterparts. Your prescriber or pharmacist can advise whether the generic is appropriate for your specific situation.

Dasatinib is a targeted oral anticancer medication known as a BCR-ABL tyrosine kinase inhibitor (TKI). In certain leukemias, a genetic abnormality called the Philadelphia chromosome produces an overactive BCR-ABL protein that drives uncontrolled cell growth. Dasatinib works by blocking BCR-ABL and several other kinases, slowing or stopping the growth of cancer cells.

Brand Sprycel is made by Bristol-Myers Squibb; generic dasatinib is available from multiple manufacturers. Dasatinib was first approved by the FDA on June 28, 2006. For clinical detail, see our dasatinib treatment guide or the NCI dasatinib page.

Dasatinib is FDA-approved to treat:

• Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, accelerated phase, and blast phase
• Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)

It is used in both newly diagnosed patients and those who are resistant to or intolerant of prior therapy. For more information, visit the NCI dasatinib page or MedlinePlus.

Standard dosing is 100 mg once daily for chronic phase CML, and 140 mg once daily for accelerated or blast phase CML and for Ph+ ALL. Dasatinib can be taken with or without food. Swallow tablets whole and do not crush, cut, or chew them. Take at approximately the same time each day. If you miss a dose, take it as soon as you remember unless it is almost time for your next dose; do not take two doses at the same time. Always follow your oncologist’s specific dosing instructions.

The most commonly reported side effects of dasatinib include fluid retention (including pleural effusion), diarrhea, headache, fatigue, nausea, rash, and low blood cell counts (myelosuppression). Most people experience some side effects, but severity varies. This is not a complete list. Always review side effects and warnings with your prescriber or pharmacist, and seek medical help right away for signs of an allergic reaction or any unexpected symptoms. For full safety information, visit the NCI dasatinib page.

Serious side effects that require prompt medical attention include severe fluid retention (pleural effusion, pericardial effusion, or pulmonary edema), severe bleeding, QT prolongation, pulmonary arterial hypertension, and severe myelosuppression (very low blood counts). Contact your care team right away if you develop shortness of breath, irregular heartbeat, unusual bleeding or bruising, or signs of infection. Your oncologist monitors for these risks throughout treatment.

Dasatinib has several clinically important interactions. Strong CYP3A4 inhibitors (including certain antifungals and some antibiotics) can increase dasatinib levels and raise the risk of toxicity. Strong CYP3A4 inducers (including certain seizure medications and rifampin) can lower dasatinib levels and reduce its effectiveness. Antacids, H2 blockers, and proton pump inhibitors may reduce dasatinib absorption and should be timed or avoided per your prescriber’s guidance. Grapefruit and grapefruit juice can also increase drug levels and should be avoided. Always give your oncologist and pharmacist a full list of medications, supplements, and foods you use.

Dasatinib can harm an unborn baby and is not recommended during pregnancy. Patients of childbearing potential are advised to use effective contraception during treatment and for a period after the last dose. Dasatinib may also pass into breast milk; breastfeeding is not recommended during treatment and for two weeks after the last dose. Discuss your family planning situation with your oncologist before starting or stopping treatment.

Dasatinib is available as oral tablets in 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg strengths. Generic dasatinib is available in all the same strengths from multiple manufacturers. QuickRx dispenses generic dasatinib based on your prescription and insurance coverage.

Call (917) 830-2525 or fill out the form on this page. A QuickRx patient navigator will reach out within one business day to review your prescription and insurance and begin identifying assistance programs you may qualify for. There is no cost for this service.